This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): nadolol
Description: INV102 is a reformulation of the already approved nadolol (Corgard). Nadolol is a non-selective beta-blocker, meaning that it non-selectively blocks both beta-1 and beta-2 receptors, but also has inverse agonism at the beta-2 receptor. While acutely, beta blockers can exacerbate asthma (the beta-2 receptor mediates contraction of smooth muscles around airways), Inversion's hypothesis is that chronic occupancy of the beta-2 receptor by beta-blockers can can lead to a compensatoryresponse with increased numbers of the receptors, resulting in greaterbronchoprotection.
Invion and 3M
In February 2014, Invion announced a collaboration with 3M Drug Delivery Systems for the development of its inhaled respiratory drug franchise. Invions agreement with 3M Drug Delivery Systems will assess the feasibility of inhaled versions of INV102 (nadolol) and INV104 (zafirlukast) delivered using 3Ms proprietary pressurized metered dose inhalation (pMDI) technology. It will also enable manufacture for toxicology, and subsequently Phase I studies, under an Invion-sponsored Investigational New Drug application, with the US Food and Drug Administration. The companies intend to develop both drug candidates through to commercialization, if they prove to be safe and effective when delivered by an inhaler.
Scrip Inverseon Inc.
Additional information available to subscribers only: